Inflammation in heart failure : pathophysiology and therapeutic strategies
© 2024. The Author(s)..
A role for inflammation in the development and progression of heart failure (HF) has been proposed for decades. Multiple studies have demonstrated the potential involvement of several groups of cytokines and chemokines in acute and chronic HF, though targeting these pathways in early therapeutic trials have produced mixed results. These studies served to highlight the complexity and nuances of how pro-inflammatory pathways contribute to the pathogenesis of HF. More recent investigations have highlighted how inflammation may play distinct roles based on HF syndrome phenotypes, findings that may guide the development of novel therapies. In this review, we propose a contemporary update on the role of inflammation mediated by the innate and adaptive immune systems with HF, highlighting differences that exist across the ejection fraction spectrum. This will specifically be looked at through the lens of established and novel biomarkers of inflammation. Subsequently, we review how improvements in inflammatory pathways may mediate clinical benefits of existing guideline-directed medical therapies for HF, as well as future therapies in the pipeline targeting HF and inflammation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Inflammation research : official journal of the European Histamine Research Society ... [et al. - 73(2024), 5 vom: 15. Apr., Seite 709-723 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boulet, Jacinthe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiomyopathy |
|---|
| Anmerkungen: |
Date Completed 29.04.2024 Date Revised 29.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00011-023-01845-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370363868 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370363868 | ||
| 003 | DE-627 | ||
| 005 | 20240430232223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240330s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00011-023-01845-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1393.xml |
| 035 | |a (DE-627)NLM370363868 | ||
| 035 | |a (NLM)38546848 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boulet, Jacinthe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inflammation in heart failure |b pathophysiology and therapeutic strategies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2024 | ||
| 500 | |a Date Revised 29.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a A role for inflammation in the development and progression of heart failure (HF) has been proposed for decades. Multiple studies have demonstrated the potential involvement of several groups of cytokines and chemokines in acute and chronic HF, though targeting these pathways in early therapeutic trials have produced mixed results. These studies served to highlight the complexity and nuances of how pro-inflammatory pathways contribute to the pathogenesis of HF. More recent investigations have highlighted how inflammation may play distinct roles based on HF syndrome phenotypes, findings that may guide the development of novel therapies. In this review, we propose a contemporary update on the role of inflammation mediated by the innate and adaptive immune systems with HF, highlighting differences that exist across the ejection fraction spectrum. This will specifically be looked at through the lens of established and novel biomarkers of inflammation. Subsequently, we review how improvements in inflammatory pathways may mediate clinical benefits of existing guideline-directed medical therapies for HF, as well as future therapies in the pipeline targeting HF and inflammation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cardiomyopathy | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Immune system | |
| 650 | 4 | |a Inflammation | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Sridhar, Vikas S |e verfasserin |4 aut | |
| 700 | 1 | |a Bouabdallaoui, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Tardif, Jean-Claude |e verfasserin |4 aut | |
| 700 | 1 | |a White, Michel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammation research : official journal of the European Histamine Research Society ... [et al. |d 1997 |g 73(2024), 5 vom: 15. Apr., Seite 709-723 |w (DE-627)NLM075208601 |x 1420-908X |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2024 |g number:5 |g day:15 |g month:04 |g pages:709-723 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00011-023-01845-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2024 |e 5 |b 15 |c 04 |h 709-723 | ||